Safety and Tolerability of Liraglutide in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

March 31, 1999

Primary Completion Date

December 31, 1999

Study Completion Date

December 31, 1999

Conditions
DiabetesHealthy
Interventions
DRUG

liraglutide

Administered as 5 single s.c. (under the skin) doses - 1.25, 2.5, 5, 10 and 20 mcg/kg once daily - in ascending order

DRUG

liraglutide

Subjects receiving the dose level 5 mcg/kg s.c. will in addition receive, after a wash-out of at least 7 days, a single i.v. (into the vein) dose of 5 mcg/kg

DRUG

placebo

Administered s.c. After a wash-out of at least 7 days, a single i.v. (into the vein) dose is administered

DRUG

placebo

Administered as 5 single s.c. (under the skin) doses - 1.25, 2.5, 5, 10 and 20 mcg/kg once daily - in ascending order

Trial Locations (1)

M15 6SH

Novo Nordisk Investigational Site, Manchester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT01507272 - Safety and Tolerability of Liraglutide in Healthy Male Volunteers | Biotech Hunter | Biotech Hunter